Nevertheless, despite the well-recognized clinical significance of claudin-4 in ovarian cancer (2, 17–19, 23), the molecular mechanisms by which it promotes the development of therapy resistance, as well as its association with genomic instability, remain poorly understood. The gene discussed is CLDN4; the disease is ovarian carcinoma.